IMTAC™ platform combines cutting-edge technologies including covalent chemistry, chemical proteomics, and quantitative mass spectrometry.  It enables covalent small molecules to perform proteome-wide screening in live cells, which results in highly selective small molecules that drug traditionally undruggable targets.

BridGene can perform IMTAC™ screening for both covalent and non-covalent molecules, setting the company apart from its peers. By combining IMTAC™ with phenotypic screening, we can also discover previously unknown mechanisms for disease treatments by identifying new targets responsible for disease characteristics in cell models, a unique differentiator from its peers.

IMTAC™ platform has the following key components:

• Proprietary proteome-trained and drug-like, covalent, tagged small molecule library.
• Live-cell and proteome-wide or target-focused screening to identify undruggable targets that interact with the small molecules.
• Mass Spec analysis to quantify the small molecules’ binding affinity against targets across the entire proteome, and to understand the precise selectivity of the small molecules.
• Proprietary novel small molecule ligands for thousands of human proteins.